Curia
26 Corporate Circle
Albany, NY 12203
T: (518) 512-2000
E: corporatecommunications@curiaglobal.com
W: www.curiaglobal.com
LinkedIn: https://www.linkedin.com/company/curia-cdmo/
Facebook: https://www.facebook.com/CuriaCDMO
Twitter: https://twitter.com/CuriaCDMO

Curia is a global contract research, development and manufacturing organization (CDMO) with over 30 years of experience. With an integrated network of 20+ facilities worldwide and a team of 3,500 dedicated professionals, we specialize in partnering with biopharmaceutical customers to bring life-changing therapies to market.

Our offerings in small molecules, generic APIs and biologics span discovery through commercialization, with integrated regulatory, analytical and sterile fill-finish capabilities. Our scientific and process experts, along with our regulatory compliant facilities, provide a best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate your research and improve patients’ lives. Visit us at curiaglobal.com.

SERVICES & CAPABILITIES

Small Molecules

Our small molecules offering spans discovery to commercial manufacturing and fill-finish services, integrating scientific, process, regulatory and analytical capabilities for API life cycle. We leverage 30+ years of expertise with 250+ medicinal chemists and 100+ development chemists combined with state-of-the-art facilities to deliver a best-in-class experience across drug substance and drug product manufacturing.

Generic APIs

With over 260 APIs produced across the US, Europe and India covering multiple therapeutic areas, we are one of the largest suppliers of generic APIs and intermediates in the industry. We bring a unique combination of experience and global facilities to meet your expanding needs.

Biologics

Our biologics offering spans discovery to clinic and fill-finish services across monoclonal antibodies, recombinant proteins and mRNA therapeutics. We currently operate six U.S. sites dedicated to biologics, with ongoing investments to modernize facilities and expand capacity.

A LEGACY OF EXCELLENCE

• Global Footprint: Operating 20+ advanced facilities with cutting-edge technology.
• Skilled Workforce: 3,500+ industry experts committed to making a difference.
• Regulatory Trust: Consistently meeting and exceeding global regulatory standards, including inspections from the US FDA, European health authorities and more.
• Leadership in Safety: The first in the industry to achieve Safebridge® Potent Compound Safety Certification.

WHITEPAPERS

Safety, containment, and analysis of highly potent compounds from development to commercialization

The benefits of end-to-end formulation and fill-finish of biologics

Bispecific antibodies unleashed

Continuous Flow – An Emerging Alternative

Strategic Government Partnerships

VIDEO

Introducing Curia: Small Molecules, Generic APIs, and Biologics (2024)